Introduction to 2a Randomized

Discover more insights into 2a Randomized

Keywords frequently search together with 2a Randomized

Narrow sentence examples with built-in keyword filters

More 2a Randomized sentence examples

10.1136/lupus-2019-lsm.183

Methods We conducted a phase 1b/2a randomized, double-blind, placebo-controlled clinical trial of oral tofacitinib, 5 mg twice daily, in 30 SLE subjects (2:1 drug to placebo ratio) with mild to moderate disease activity, stratified by the presence or absence of STAT4 risk allele.

Full Text

Learn more from 2a Randomized

Keywords related to 2a

2a Inhibition 2a Clinical 2a Regulatory 2a Trial 2a Peptides 2a Protease 2a Peptide 2a Adenosine 2a Signaling 2a Receptor 2a Activation 2a Protein 2a Receptors 2a Inhibitor Explore More

Keywords related to Randomized

Stratified Randomized 27 Randomized Crossover Randomized Children Randomized 1 Randomized Therapy Randomized Superiority Randomized Concept Randomized Prospective Randomized Program Randomized Z Randomized Orthopaedic Randomized Two Stage Randomized 18 Randomized Subjects Randomized Large Scale Randomized Failure Randomized Multi Arm Randomized Three Randomized 12 Randomized Centre Randomized Treatment Randomized Open Label Non Randomized 16 Randomized Exercise Randomized Short Term Randomized Partially Randomized Monocentric Randomized Pragmatic Non Randomized 14 Randomized Iib Randomized Preclinical Randomized Assessor Blinded Randomized Interventional Randomized Clinical Randomized Two Arm Randomized Iia Randomized Four Randomized Protocol Randomized Three Armed Randomized Multiple Randomized Diabetes Randomized Recent Randomized Non Blinded Randomized Eight Randomized Orthodontic Randomized Simple Randomized Multicentered Randomized Follow Up Randomized Efficacy Randomized Explore More

2a Randomized

Encyclopedia

Aug 19, 2022

What is/are 2a Randomized?

2a Randomized - Methods We conducted a phase 1b/2a randomized, double-blind, placebo-controlled clinical trial of oral tofacitinib, 5 mg twice daily, in 30 SLE subjects (2:1 drug to placebo ratio) with mild to moderate disease activity, stratified by the presence or absence of STAT4 risk allele. ^[1]